1. CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS. (12th June 2019) Authors: Bachanova, V.; Westin, J.; Tam, C.; Borchmann, P.; Jaeger, U.; McGuirk, J.; Holte, H.; Waller, E.; Jaglowski, S.; Bishop, M.; Andreadis, C.; Foley, S.R.; Fleury, I.; Teshima, T.; Mielke, S.; Salles, G.; Ho, P.J.; Izutsu, K.; Maziarz, R.; Van Besien, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 308 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS. (June 2017) Authors: Schuster, S.J.; Bishop, M.R.; Tam, C.; Waller, E.K.; Borchmann, P.; Mcguirk, J.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.; Fleury, I.; Bachanova, V.; Foley, S.R.; Ho, P.J.; Mielke, S.; Holte, H.; Anak, O.; Pacaud, L.; Awasthi, R.; Tai, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. (12th June 2019) Authors: Jaeger, U.; Tam, C.; Borchmann, P.; McGuirk, J.; Holte, H.; Waller, E.; Jaglowski, S.; Andreadis, C.; Foley, S.R.; Fleury, I.; Westin, J.; Teshima, T.; Mielke, S.; Salles, G.; Ho, P.J.; Izutsu, K.; Schuster, S.; Bachanova, V.; Maziarz, R.; Van Besien, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 505 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗